Print

Active Biotech's Cancer Project ANYARA Proven Safe in Combination with Taxotere®

2007-10-24

Lund, Sweden, October 24, 2007 - Active Biotech AB (OMX Nordic:ACTI) has presented the final results of the previously reported clinical Phase I study of the cancer project ANYARA in combination with Taxotere® in patients with non-small cell lung cancer.
The presentation was made at the AACR-NCI-EORTC1) conference "Molecular Targets and Cancer Therapeutics" in San Francisco, USA.
The results2) show that ANYARA can be given safely in combination with Taxotere® (Sanofi-Aventis), an established drug for the treatment of non-small cell lung cancer.
Thirteen patients with advanced non-small cell lung cancer were included in the study. Observed side effects during ANYARA treatment were expected and included transient fever, hypotension and nausea. Other toxicities recorded in the study were typical of Taxotere®. Out of ten evaluable patients, two received a partial response (a tumor reduction of at least 30 percent), including one patient that had previously failed with Taxotere® treatment and 5 patients had stable disease.
ANYARA is presently developed primarily for the treatment of Renal Cancer and a pivotal phase II/III is ongoing with an interim analysis planned for mid 2008.
Active Biotech AB (publ)
Sven Andréasson
President and CEO
2) View the complete poster "An open label phase I study of ABR-217620 in combination with docetaxel in patients with NSCLC" at www.activebiotech.com
For further information, please contact
Sven Andréasson, President & CEO
+46 (0)46 19 20 49
Tomas Leanderson, Chief Scientific Officer
+46 (0)46 19 20 95
tomas.leanderson@activebiotech.com
Notes to editors
About ANYARA
Active Biotech's ANYARA project develops a drug for use in cancer targeted therapy, primarily for the treatment of renal cell cancer. A Phase II/III study is ongoing since the end of 2006. It is a randomized study of ANYARA in combination with interferon-alpha, compared with only interferon-alpha, in patients with advanced renal cell cancer.
The primary clinical effect parameter for this study is survival and it will include approximately 500 patients at 45 clinics in Europe. Expected survival with conventional treatment for these patients is 10-15 months and the length of the study will depend on the patients' disease progression. An interim analysis based on approximately 200 patients is scheduled for mid 2008.
About Active Biotech
Active Biotech AB (OMX Nordic:ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immuno-modulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the autoimmunity project I-3D is in preclinical development.
Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50

pdf



Back